SG11201500980WA - Clostridium difficile polypeptides as vaccine - Google Patents

Clostridium difficile polypeptides as vaccine

Info

Publication number
SG11201500980WA
SG11201500980WA SG11201500980WA SG11201500980WA SG11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA
Authority
SG
Singapore
Prior art keywords
vaccine
clostridium difficile
polypeptides
difficile polypeptides
clostridium
Prior art date
Application number
SG11201500980WA
Other languages
English (en)
Inventor
Cesira Galeotti
Rosanna Leuzzi
Mariagrazia Pizza
Maria Scarselli
Meera Unnikrishnan
Manuele Martinelli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201500980WA publication Critical patent/SG11201500980WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201500980WA 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine SG11201500980WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
SG11201500980WA true SG11201500980WA (en) 2015-04-29

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500980WA SG11201500980WA (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Country Status (13)

Country Link
US (1) US9932374B2 (enExample)
EP (1) EP2897637A1 (enExample)
JP (1) JP2015529677A (enExample)
KR (1) KR20150056540A (enExample)
CN (1) CN104582722A (enExample)
AU (1) AU2013319821A1 (enExample)
BR (1) BR112015004629A2 (enExample)
CA (1) CA2882620A1 (enExample)
IL (1) IL237172A0 (enExample)
MX (1) MX2015002485A (enExample)
RU (1) RU2015106916A (enExample)
SG (1) SG11201500980WA (enExample)
WO (1) WO2014045226A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619871B (zh) 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
US10533036B2 (en) 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
BR112020024514A2 (pt) 2018-06-19 2021-03-02 Glaxosmithkline Biologicals S.A. composição imunogênica
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059053A1 (en) * 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
WO2001070955A2 (en) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7226597B2 (en) * 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
JP2011512817A (ja) * 2008-02-28 2011-04-28 スリーエム イノベイティブ プロパティズ カンパニー クロストリジウム・ディフィシル胞子に対する抗体及びその使用
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
JP2013512916A (ja) 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン
KR20140101835A (ko) * 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신

Also Published As

Publication number Publication date
IL237172A0 (en) 2015-04-30
KR20150056540A (ko) 2015-05-26
RU2015106916A (ru) 2016-11-10
AU2013319821A1 (en) 2015-02-26
MX2015002485A (es) 2015-06-05
WO2014045226A1 (en) 2014-03-27
US20150315248A1 (en) 2015-11-05
CN104582722A (zh) 2015-04-29
US9932374B2 (en) 2018-04-03
CA2882620A1 (en) 2014-03-27
BR112015004629A2 (pt) 2017-11-21
EP2897637A1 (en) 2015-07-29
JP2015529677A (ja) 2015-10-08

Similar Documents

Publication Publication Date Title
IL291571A (en) cx3cr1 binding polypeptides
EP2807186A4 (en) DIFFICULT CLOSTRIDIUM VACCINES COMPRISING RECOMBINANT TOXINS
IL235890A0 (en) vaccine
GB201218427D0 (en) Blender
PL2647387T3 (pl) Kompozycja szczepionki
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
GB201220474D0 (en) Polypeptides
GB201223386D0 (en) Vaccine
IL232957A0 (en) A composition based on clostridium difficile toxin
SG11201406301TA (en) Clostridium difficile antigens
SG11201500980WA (en) Clostridium difficile polypeptides as vaccine
EP2925362A4 (en) ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
GB201217488D0 (en) Blender
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
IL237571A0 (en) Tiotropium preparations
GB201223114D0 (en) Novel peptide
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
HUE036243T2 (hu) PSF1-származék peptid
IL231661A0 (en) Clostridium difficile antibodies
GB201121149D0 (en) Clostridium difficile toxin-based vaccine
GB201220328D0 (en) Peptides